Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
- Associated Conditions
- -
- Associated Therapies
- -
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04708067
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04648826
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT04560686
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 11
- Registration Number
- NCT04489940
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Medical Oncology Hematology Consultants, PA, Helen F. Graham Cancer Center, Suite 3400, Newark, Delaware, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
- Conditions
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-07-26
- Target Recruit Count
- 49
- Registration Number
- NCT04481256
- Locations
- 🇳🇱
Academic Medical Center, Medical Oncology, Amsterdam, Netherlands
First in Human Study of M6223
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-12-08
- Target Recruit Count
- 58
- Registration Number
- NCT04457778
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 7
- Registration Number
- NCT04428047
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut Curie, Paris, France
🇫🇷Institut de cancérologie de Lorraine, Vandoeuvre les nancy, France
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 38
- Registration Number
- NCT04396886
- Locations
- ðŸ‡ðŸ‡°
Queen Mary Hospital, Hong Kong, Hong Kong
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT04396535
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT04349280
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.